Organogenesis Holdings Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Organogenesis Holdings kazanç ve gelirin sırasıyla yıllık 123.3% ve 4.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 122.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 1.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

123.3%

Kazanç büyüme oranı

122.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.4%
Gelir büyüme oranı	4.6%
Gelecekteki özkaynak getirisi	1.2%
Analist kapsamı	Low
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Organogenesis: Lurking Disruption With Recovery To Follow

Oct 15

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Sep 09

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:ORGO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	511	13	N/A	N/A	3
12/31/2025	470	2	N/A	N/A	4
12/31/2024	464	-9	N/A	N/A	4
9/30/2024	455	-7	4	14	N/A
6/30/2024	448	-17	9	22	N/A
3/31/2024	435	6	7	26	N/A
12/31/2023	433	5	7	31	N/A
9/30/2023	449	13	-4	28	N/A
6/30/2023	457	10	-19	17	N/A
3/31/2023	461	13	-16	18	N/A
12/31/2022	451	16	-9	25	N/A
9/30/2022	463	59	7	35	N/A
6/30/2022	460	71	23	57	N/A
3/31/2022	462	83	32	65	N/A
12/31/2021	467	94	31	62	N/A
9/30/2021	446	62	36	67	N/A
6/30/2021	433	69	28	48	N/A
3/31/2021	379	43	3	21	N/A
12/31/2020	338	17	-12	5	N/A
9/30/2020	306	-5	-40	-24	N/A
6/30/2020	270	-37	-50	-38	N/A
3/31/2020	266	-42	-51	-41	N/A
12/31/2019	261	-39	-40	-34	N/A
9/30/2019	250	-46	-48	-45	N/A
6/30/2019	236	-48	-65	-62	N/A
3/31/2019	215	-58	-68	-66	N/A
12/31/2018	193	-65	-62	-61	N/A
9/30/2018	183	-60	-48	-46	N/A
6/30/2018	184	-52	N/A	-25	N/A
3/31/2018	187	-32	N/A	-9	N/A
12/31/2017	199	-9	N/A	-3	N/A
12/31/2016	139	-17	N/A	-5	N/A
12/31/2015	99	-24	N/A	-10	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ORGO önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: ORGO önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: ORGO önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: ORGO şirketinin gelirinin (yıllık 4.6% ) US pazarından (yıllık 9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ORGO şirketinin gelirinin (yıllık 4.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ORGO 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 1.2 %).

Organogenesis Holdings Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus estimates of losses per share improve by 64%

Price target increased by 7.4% to US$4.70

Consensus EPS estimates fall by 492%

Price target decreased by 11% to US$4.17

Consensus EPS estimates fall by 267%

Consensus EPS estimates upgraded to US$0.01 loss

Recent updates

Consensus estimates of losses per share improve by 64%

Price target increased by 7.4% to US$4.70

Organogenesis Holdings Inc. announced that it expects to receive $130 million in funding from Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P

New minor risk - Share price stability

Organogenesis Holdings Inc. announced that it expects to receive $130 million in funding from Avista Healthcare Partners

Organogenesis Holdings Inc. Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Organogenesis Holdings Inc. to Report Q3, 2024 Results on Nov 12, 2024

Organogenesis: Lurking Disruption With Recovery To Follow

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Consensus EPS estimates fall by 492%

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.04 profit in 2Q 2023)

Organogenesis Holdings Inc. Shares Renu Program Update

Investor sentiment deteriorates as stock falls 18%

Organogenesis Holdings Inc. to Report Q2, 2024 Results on Aug 08, 2024

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Price target decreased by 11% to US$4.17

Consensus EPS estimates fall by 267%

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Investor sentiment improves as stock rises 25%

Consensus EPS estimates upgraded to US$0.01 loss

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

First quarter 2024 earnings released: US$0.016 loss per share (vs US$0.023 loss in 1Q 2023)

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Investor sentiment deteriorates as stock falls 20%

Organogenesis Holdings Inc. to Report Q1, 2024 Results on May 09, 2024

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Chief Operating Officer exercised options to buy US$432k worth of stock.

Consensus EPS estimates fall from profit to US$0.013 loss

New minor risk - Earnings quality

Full year 2023 earnings: EPS and revenues miss analyst expectations

Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024

Investor sentiment improves as stock rises 20%

Organogenesis Holdings Inc. to Report Q4, 2023 Results on Feb 29, 2024

Insider recently sold US$77k worth of stock

Investor sentiment improves as stock rises 17%

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Investor sentiment improves as stock rises 22%

Consensus forecasts updated

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 15%

High number of new directors

Organogenesis Holdings Inc. to Report Q3, 2023 Results on Nov 09, 2023

Organogenesis Holdings Inc. Withdraws Earnings Guidance for the the 2023

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 16%

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Investor sentiment deteriorates as stock falls 15%

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Investor sentiment improves as stock rises 23%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improves as stock rises 16%

Insider recently sold US$104k worth of stock

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorates as stock falls 17%

Organogenesis Holdings Inc. to Report Q4, 2022 Results on Mar 01, 2023

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.098 in 3Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Organogenesis Holdings Inc. to Report Q3, 2022 Results on Nov 09, 2022